Sarukhani Mohammad, Haghdoost-Yazdi Hashem, Sarbazi Golezari Ali, Babayan-Tazehkand Arvin, Dargahi Tahere, Rastgoo Nafiseh
a Cellular and Molecular Research Center , Qazvin University of Medical Sciences , Qazvin , Iran.
b Student Research Committee , Qazvin University of Medical Sciences , Qazvin , Iran.
Neurol Res. 2018 Jul;40(7):523-531. doi: 10.1080/01616412.2017.1390903. Epub 2018 May 4.
Studies have shown that hydrogen sulfide (HS), a gaseous neurotransmitter, has neuroprotective effect. Here, we evaluated the neuroprotective activity of HS in acute 6-hydroxydopamine (6-OHDA) animal model of Parkinson's disease (PD).
6-OHDA was injected through stereotaxic surgery into medial forebrain bundle (MFB) of the right hemisphere to induce severe and fast degeneration in dopaminergic neurons of substantia nigra (SN). NaHS, as donor of HS, was daily injected at doses of 3 and 5.6 mg/kg for seven days starting a few hours before the surgery. A series of behavioral tests were carried out and then, remaining tyrosine hydroxylase (TH)-positive neurons in substantia nigra pars compacta (SNc) was determined using immunohistfluresance staining. Striatal dopamine level and oxidative stress markers were also measured in the brain homogenates using immunosorbent assay kits.
NaHS attenuated apomorphine-induced rotational activity, decreased bias swings in elevated body swing test and increased falling time in rotarod test. Our histological and biochemical data demonstrated that NaHS treatment increases the survival of TH-positive neurons in SNc and also reduces the decreasing effect of 6-OHDA on striatal dopamine level. NaHS also reduced 6-OHDA-induced malondialdehyde overproduction but had no effect on the superoxide dismutase and glutathione peroxidase activity.
Our results show that HS produces significant antiparkinsonism and neuroprotective effects against 6-OHDA neurotoxicity. Since injection of 6-OHDA into MFB produces severe lesion in SN dopaminergic neurons similar to this lesion in the onset of PD in human being, our data recommend HS as potential therapeutic target for treatment of this disease.
研究表明,气态神经递质硫化氢(HS)具有神经保护作用。在此,我们评估了HS在帕金森病(PD)急性6-羟基多巴胺(6-OHDA)动物模型中的神经保护活性。
通过立体定向手术将6-OHDA注射到右半球内侧前脑束(MFB)中,以诱导黑质(SN)多巴胺能神经元严重且快速退化。作为HS供体的硫氢化钠(NaHS)在手术前数小时开始,每天以3和5.6mg/kg的剂量注射7天。进行了一系列行为测试,然后使用免疫荧光染色法测定黑质致密部(SNc)中剩余的酪氨酸羟化酶(TH)阳性神经元。还使用免疫吸附测定试剂盒在脑匀浆中测量纹状体多巴胺水平和氧化应激标志物。
NaHS减弱了阿扑吗啡诱导的旋转活动,减少了高架体摆动试验中的偏摆,并增加了转棒试验中的跌落时间。我们的组织学和生化数据表明,NaHS治疗可增加SNc中TH阳性神经元的存活,并还可降低6-OHDA对纹状体多巴胺水平的降低作用。NaHS还减少了6-OHDA诱导的丙二醛过量产生,但对超氧化物歧化酶和谷胱甘肽过氧化物酶活性没有影响。
我们的结果表明,HS对6-OHDA神经毒性具有显著的抗帕金森病和神经保护作用。由于将6-OHDA注射到MFB中会在SN多巴胺能神经元中产生严重损伤,类似于人类PD发病时的这种损伤,我们的数据推荐HS作为治疗该疾病的潜在治疗靶点。